Amgen to present GLAGOV trial results at AHA Scientific Sessions
GLAGOV stands for GLobal Assessment of Plaque ReGression with a PCSK9 Antibody as Measured by IntraVascular Ultrasound. The AHA Scientific Sessions will be held in New Orleans Nov. 12-16.
"Amgen is committed to unlocking the full potential of biotechnology in the global fight against cardiovascular disease," Amgen Executive Vice President of Research and Development Dr. Sean E. Harper said. "The robust clinical, observational and health economics data to be presented at AHA 2016 continue to grow our body of knowledge and demonstrate our dedication to improving care for patients with cardiovascular disease."
The focus of the GLAGOV trial was Repatha. The study assessed whether or not atherosclerotic plaque built-up in patients' coronary arteries would be modified by Repatha, which is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor designed to treat patients who have high low-density LDL-C (lipoprotein cholesterol). The patients taking part in the trial were previously treated optimized statin therapy.
Amgen previously announced that the GLAGOV trial met both its primary and secondary goals.